unknown by Małek, Łukasz A. et al.
Address for correspondence: Łukasz A. Małek, MD, PhD, Department of Interventional Cardiology and Angiology,  
Institute of Cardiology, ul. Alpejska 42, 04–628 Warszawa, Poland, tel: + 48 22 34 34 657, fax: + 48 22 613 38 19,  
e-mail: lmalek@ikard.pl
Received: 30.01.2013 Accepted: 19.02.2013
original article
Cardiology Journal 
2013, Vol. 20, No. 5, pp. 552–559
DOI: 10.5603/CJ.2013.0141
Copyright © 2013 Via Medica
ISSN 1897–5593
552 www.cardiologyjournal.org
Late percutaneous coronary intervention for  
an occluded infarct-related artery in patients with 
preserved infarct zone viability: A pooled analysis 
of cardiovascular magnetic resonance studies
Łukasz A. Małek1, Joao C. Silva2, Nick G. Bellenger3, Jose C. Nicolau2,  
Mariusz Kłopotowski1, Mateusz Śpiewak4, Carlos H. Rassi5, Zbigniew Lewandowski6, 
Mariusz Kruk4, Carlos E. Rochitte5, Witold Rużyłło4, Adam Witkowski1 
1Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland 
2Acute Coronary Disease Unit, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil 
3Royal Devon and Exeter Hospital, Exeter, United Kingdom 
4Department of Coronary Heart Disease and Structural Heart Diseases, Institute of Cardiology, Warsaw, Poland 
5Cardiovasular Magnetic Resonance and Computed Tomography, Heart Institute (InCor),  
University of São Paulo Medical School, São Paulo, Brazil 
6Department of Epidemiology, Medical University of Warsaw, Poland
Abstract
Background: The results of clinical trials assessing the effect of late opening of infarct-related 
artery (IRA) on left ventricular ejection fraction (LVEF) and size in stable patients are equi-
vocal, which may be related to the fact that the presence of viability was not a requirement for 
randomization in these trials. The aim of the study was to assess the influence of late percu-
taneous coronary intervention (PCI) with optimal medical therapy (OMT) vs. OMT alone on 
cardiac function and remodeling in patients presenting infarct zone with preserved viability 
on cardiovascular magnetic resonance (CMR).
Methods: The analysis included pooled data of 43 patients from 3 randomized studies. All 
patients underwent CMR before randomization, but only in 1 previously unpublished study 
was preserved viability required for randomization to treatment. Follow-up CMR was perfor-
med after 6–12 months. 
Results: Late PCI with OMT led to improved LVEF (+5 ± 7% vs. –1 ± 6%, p = 0.005), 
decreased left ventricular end-systolic volume (–11 ± 19 mL vs. 12 ± 40 mL, p = 0.02) and  
a trend towards a decrease in end-diastolic volume (–7 ± 27 mL vs. 15 ± 47 mL, p = 0.07) in 
comparison to OMT alone. Increased LVEF and decreased left ventricular volumes were observed 
after the analysis was restricted to patients with left anterior descending artery (LAD) occlusion. 
Conclusions: In patients with the presence of infarct zone viability, OMT with late PCI for 
an occluded IRA (particularly LAD) is associated with improvement of left ventricular systolic 
function and size over OMT alone. (Cardiol J 2013; 20, 5: 552–559)
Key words: myocardial infarction, occluded artery, infarct-related artery,  
viability, percutaneous coronary intervention, optimal medical treatment 
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Introduction
Restoration of blood flow to an infarct-rela-
ted artery (IRA) in the first 12 h of evolution is 
a cornerstone of contemporary treatment of acute 
myocardial infarction (MI) [1, 2]. It decreases the 
infarct size, preventing the expansion of myocardial 
necrosis and its consequences [1, 2]. However, due 
to their late presentation, up to one third of patients 
do not receive reperfusion therapy [3]. 
Randomized clinical trials assessing the be-
nefits of late percutaneous coronary intervention 
(PCI) on top of optimal medical therapy (OMT) 
of a totally occluded IRA, in comparison to OMT 
alone, showed equivocal results [4–8], with most 
of them failing to demonstrate any significant 
improvement in cardiac systolic function and/or 
remodeling with PCI [4, 5, 8]. Lack of significant 
benefit of the invasive approach on left ventricular 
(LV) performance in this group of patients could 
have been responsible for a similar or even higher 
rate of clinical end-points observed in this group 
during follow-up in comparison to OMT alone 
[4, 6, 9]. These results might have been impacted by 
the fact that the presence of infarct zone viability 
was not required for randomization in these trials, 
and therefore late PCI was performed in patients 
both with and without viability [10, 11].
This hypothesis is supported by the results of 
a meta-analysis on patients with chronic ischemia, 
which showed that only patients with myocardial 
viability [assessed with echocardiography or single-
-photon emission computed tomography (SPECT)] 
benefited from revascularization [12]. Also studies 
with the use of cardiovascular magnetic resonance 
(CMR) performed in the setting of chronic ischemia 
demonstrated that patients with LV systolic dysfun-
ction and preserved myocardial viability (defined 
by means of low dose dobutamine test or delayed 
enhancement) benefited from revascularization in 
terms of cardiac function and remodeling, and/or 
improved survival [13–16]. 
The aim of this study was to determine 
whether late opening of an occluded IRA in pa-
tients with the presence of infarct zone viability 
on CMR improved cardiac function and volume 
over OMT alone. 
Methods
Study group
Initially the study was planned as a single 
center randomized clinical trial: Cardiovascular 
Magnetic Resonance for the Occluded Infarct-
-Related Artery Treatment (COAT; Clinical Trials.
gov NCT00968383). It included patients who met 
the Occluded Artery Trial (OAT) inclusion crite-
ria but did not meet the OAT exclusion criteria 
as reported previously [17], and additionally had 
preserved infarct zone viability. Preserved infarct 
zone viability was defined as delayed enhancement 
(DE) not exceeding 50% of transmurality in at 
least half of the segments of the infarct zone on 
initial CMR examination. Infarct zone included all 
LV segments with signal intensity > 2 standard 
deviations of the mean signal intensity of the remote 
myocardium on dark-blood T2-weighted short-tau 
inversion-recovery fast-spin echo sequences indi-
cating myocardial edema [18, 19]. Eligible patients 
were randomized (1:1 ratio) to PCI + OMT or to 
OMT alone and followed-up for 6 months until 
a second CMR examination. All CMR studies were 
performed with a 1.5 T scanner (Avanto, Siemens, 
Erlangen, Germany). 
The study was prematurely stopped due to low 
enrollment. However we decided to pool individual 
data from the COAT trial with individual data ex-
tracted from previously published randomized stu-
dies on late opening of a totally occluded IRA with 
the use of CMR, but without the viability criterion 
used for randomization. The criteria for inclusion 
into the pooled analysis were: (a) total occlusion of 
an IRA (TIMI flow 0–1) within the first month after 
MI, (b) stable clinical condition of patients (lack 
of symptoms of heart failure or ischemia at rest), 
(c) randomization to PCI + OMT or OMT alone, 
(d) at baseline, presence of infarct zone viability by 
CMR, (e) CMR data on LV ejection fraction (LVEF), 
LV end-diastolic volume (LVEDV) and LV end-
-systolic volume (LVESV) at baseline and at follow-
-up. Two studies met such inclusion criteria [7, 20].
In brief, one by Bellenger et al. [20] (the TOAT 
trial substudy) included stable patients with occlu-
ded left anterior descending artery (LAD) between 
3 and 28 days after MI and non-significant disease 
in other coronary arteries [5]. PCI was performed 
at the time of angiography or within 2 weeks of 
angiography. Practical considerations therefore 
precluded baseline CMR of all patients before an-
giography. In these cases it was done shortly after 
PCI. In all other cases CMR was performed before 
PCI. All CMR studies were done with the use of 
a 1.5 T scanner (Picker Edge, Picker, Cleveland, 
OH, USA) and repeated after 1 year post-MI. Myo-
cardial viability was defined at baseline by means 
of low dose dobutamine test (up to 10 μg/kg/min). 
Infarct zone viability in individual patients was 
not analyzed in that study. Therefore, for the pur-
pose of the current analysis, infarct zone viability 
Figure 1. The scheme of pooled data analysis; COAT — 
Cardiovascular magnetic resonance for the Occluded 
infarct-related Artery Treatment; LAD — left anterior 
descending artery; PCI — percutaneous coronary in-
tervention; OMT — optimal medical therapy; IRA — 
infarct-related artery.
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was defined as a wall motion improvement by at 
least one full grade (where 1: normal wall motion, 
2: hypokinetic, 3: akinetic and 4: dyskinetic) in at 
least 2 LV dysfunctional segments. 
The other by Silva et al. [7] included patients 
with anterior MI admitted between 12 h and 14 days 
after MI. All patients underwent CMR with 
a 1.5 T scanner (SIGNA, CV/I, General Medical 
Electric Systems, Waukesha, MN, USA) and DE 
technique before PCI or shortly after the procedu-
re. Neither for this study was infarct zone viability 
analyzed with CMR previously reported. Therefore 
for the purpose of the current analysis, infarct zone 
viability was defined as DE not exceeding < 50% 
of transmurality in at least half of the segments 
supplied by the LAD. A second CMR examination 
was performed after 6 months of follow-up.
Both of the studies published previously in-
cluded only patients with LAD occlusion, while 
the COAT trial included also patients with right 
coronary artery (RCA) occlusion. Therefore, to 
limit the inclusion bias, we decided to perform an 
additional analysis restricted only to patients with 
LAD occlusion. The scheme of pooled data analysis 
is presented in Figure 1.
Institutional review boards approved the stu-
dy protocols, and each patient provided a written 
informed consent. 
Study end-points
The study end-points included change in LVEF, 
LVEDV and LVESV at follow-up in patients trea-
ted with late PCI + OMT in comparison to those 
treated with OMT alone. 
Statistical analysis
Baseline characteristics of study patients 
were summarized in terms of frequencies and 
percentages for categorical variables. For conti-
nuous variables means and standard deviations or 
medians and interquartile ranges were utilized, 
taking into account the assessment of normality 
of distribution by means of the Shapiro-Wilk test. 
Categorical variables were compared by either 
Fisher‘s exact or c2 test and continuous variables 
by the Student t test or the Mann-Whitney test 
for unpaired samples, where appropriate. Changes 
in cardiac function and size with intervention 
(PCI + OMT or OMT alone) were analyzed with 
a paired samples Student t test. All tests were 
2-sided with the significance level of p < 0.05. 
Statistical analyses were performed with the use 
of the SAS 9.3.1 software (SAS Institute Inc., Cary, 
NC, USA) [21].
Results
The characteristics of the analyzed clinical 
trials are presented in Table 1. All patients recei-
ved aspirin and angiotensin converting enzyme 
inhibitor (ACE-I) and most of them were treated 
with beta-blockers and statins. Clopidogrel was 
administered to all patients in the COAT trial and to 
patients who received stents in the other 2 studies. 
Only few patients received diuretics. 
Pooling of data revealed 21 patients treated 
with late PCI + OMT and 22 patients treated with 
OMT alone. There were no differences in baseline 
characteristics of the population in both treatment 
arms, except a more frequent use of clopidogrel 
in patients treated invasively, as described above 
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(Table 2). Importantly, there were no differences 
in baseline LVEF, LVEDV and LVESV. Successful 
PCI was performed in 97% of cases (in 1 patient 
it was impossible to cross the occlusion site with 
a guidewire).
Late PCI with OMT led to an increase in LVEF 
(+5 ± 7% vs. –1 ± 6%, p = 0.005), decrease in 
LVESV (–11 ± 19 mL vs. 12 ± 40 mL, p = 0.02) 
and a trend towards a decrease in LVEDV (–7 ± 
±  27 mL vs. 15 ± 47 mL, p = 0.07) in comparison 
to OMT alone, as shown in Figures 2A–C.
An additional analysis was performed for 
patients with LAD occlusion only. It excluded 
7 patients with RCA occlusion from the COAT. 
The LAD only subgroup consisted of 19 patients 
treated with late PCI + OMT and 17 patients who 
received OMT alone (Fig. 1).
A comparison of patients with LAD occlusion 
treated with PCI + OMT vs. OMT alone did not 
demonstrate significant differences in baseline 
characteristics except a more frequent use of clo-
pidogrel in patients treated invasively as described 
Table 1. Characteristics of the analyzed clinical trials.
COAT trial Silva et al. [7] Bellenger et al. [20]
Years of the study 2009–2011 1999–2001 1997–1999
Infarct-related artery LAD: 36%, RCA: 64% LAD: 100% LAD: 100%
Method of viability assessment Delayed  
enhancement
Delayed  
enhancement
Low-dose  
dobutamine
No. of randomized patients with  
preserved infarct zone viability
11 (100%) 23/30 (76%) 9/23 (39%)
Treatment:
PCI + OMT 5 (45%) 12 (53%) 4 (44%)
OMT alone 6 (55%) 11 (47%) 5 (56%)
Follow-up [months] 6 12 6 
Time between MI and randomization 3–28 days 12 h–14 days 3–28 days
Time between MI and CMR [days] 13 ± 5 11 ± 4 54 ± 18
Male sex 9 (82%) 15 (65%) 9 (100%)
Age [years] 58 ± 13 54 ± 9 57 ± 11
Risk factors:
Diabetes 0 (0%) 3 (13%) 3 (33%)
Hypertension 9 (82%) 10 (44%) 3 (33%)
Dyslipidaemia 7 (64%) 6 (26%) 3 (33%)
Current smoker 2 (18%) 10 (44%) 5 (55%)
TIMI flow:
0 8 (73%) 14 (61%) 6 (66%)
1 3 (27%) 9 (39%) 3 (33%)
Multivessel disease 1 (9%) 15 (65%) 0 (0%)
Medications on discharge:
Aspirin 11 (100%) 23 (100%) 9 (100%)
Clopidogrel* 11 (100%) 12 (52%) 4 (44%)
Statin 11 (100%) 8 (35%) 9 (100%)
Beta-blocker 11 (100%) 21 (91%) 8 (89%)
ACE-I 11 (100%) 23 (100%) 9 (100%)
Diuretic 1 (9%) 5 (22%) 0 (0%)
LVEF at baseline [%] 59 ± 9 45 ± 9 50 ± 14
LVEDV at baseline [mL] 172 ± 43 149 ± 37 180 ± 46
LVESV at baseline [mL] 73 ± 26 82 ± 28 95 ± 45
*COAT — for 12 months in all patients, Silva et al. [7] — for 30 days after PCI only, Bellenger et al. [20] — for 2 weeks after PCI only;  
ACE-I — angiotensin converting enzyme; CMR — cardiovascular magnetic resonance; LAD — left anterior descending artery; LVEF — left 
ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; LVESV — left ventricular end-systolic volume; MI — myocardial 
infarction; OMT — optimal medical therapy; PCI — percutaneous coronary; RCA — right coronary artery; TIMI — thrombolysis in myocar-
dial infarction
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previously. Importantly, there were no differences 
in baseline cardiac function and size between pa-
tients treated invasively and conservatively (LVEF 
48 ± 10% vs. 48 ± 12%, p = 0.97; LVEDV 162 ± 
± 42 mL vs. 152 ± 45 mL, p = 0.51; LVESV 85 ± 
± 29 mL vs. 81 ± 38 mL, p = 0.72). 
In the LAD occlusion subgroup, late PCI with 
OMT led to an increase in LVEF (+4 ± 6% vs. 
–2 ± 7%, p = 0.004) and a decrease in LVEDV 
(–7 ± 28 mL vs. 23 ± 48 mL, p = 0.03) and LVESV 
(–11 ± 19 mL vs. 18 ± 43 mL, p = 0.01) in com-
parison to OMT alone as shown in Figures 2D–F.
During follow-up there was only one important 
clinical event in the OMT group (non-fatal MI) and 
no events in the PCI group. 
Discussion
Previous studies assessing cardiac function 
and remodeling after late PCI for a totally occluded 
IRA with OMT vs. OMT alone showed conflicting 
results [4–8]. In most of the studies, there was no 
difference in LVEF at follow-up for the 2 strategies 
[4, 5, 8]. Only few trials demonstrated an impro-
vement in cardiac systolic function after late PCI, 
but changes in LV size were either not analyzed 
in these studies [6] or no significant influence of 
the invasive strategy on cardiac remodeling was 
observed [7]. Equivocal results were also observed 
for the influence of late PCI on LV remodeling. 
Horie et al. [4] demonstrated an improvement in 
LVEDV and LVESV with late opening of an IRA, 
while other studies showed no differences in these 
parameters [7, 8] or even adverse effects of late 
PCI on LV size [5]. Lack of influence of late PCI on 
cardiac function and remodeling may explain the 
lack of benefits of late PCI in terms of reduction of 
negative outcomes observed in most trials [4, 6, 9]. 
It should be noted that none of the randomized 
clinical trials on late PCI for an occluded IRA inclu-
ded the infarct zone viability criterion as a require-
ment for randomization to treatment, which could 
have influenced the results. It is likely that changes 
in LV function and size after MI in patients with in-
farct zone necrosis were similar irrespective of the 
treatment strategy as long as OMT was introduced. 
On the other hand, restoration of blood flow and 
oxygen supply to the dysfunctional, but viable (hi-
bernating) segments of the LV should improve their 
systolic function and prevent LV remodeling [22]. 
This issue has been also raised by commen-
tators of the OAT trial — the largest clinical trial 
Table 2. Baseline characteristics of patients treated with PCI + OMT or with OMT alone — pooled data 
from the 3 studies.
PCI + OMT (n = 21) OMT alone (n = 22) P
Male sex 16 (76%) 18 (82%) 0.72
Age [years] 58 ± 11 54 ± 10 0.24
Risk factors:
Diabetes 2 (10%) 4 (18%) 0.66
Hypertension 10 (48%) 12 (54%) 0.88
Dyslipidaemia 9 (43%) 7 (32%) 0.66
Current smoker 6 (29%) 11 (50%) 0.26
TIMI flow: 0.72
0 10/17 (59%) 12/17 (71%)
1 7/17 (41%) 5/17 (29%)
Multivessel disease 8 (38%) 8 (36%) 1.00
Medications on discharge:
Aspirin 21 (100%) 22 (100%) 1.00
Clopidogrel* 21 (100%) 6 (27%) 0.0001
Statin 14 (67%) 14 (64%) 1.00
Beta-blocker 21 (100%) 19 (86%) 0.23
ACE-I 21 (100%) 22 (100%) 1.00
Diuretic 2 (10%) 4 (18%) 0.66
Mean LVEF at baseline [%] 49 ± 11 50 (12) 0.77
Mean LVEDV at baseline [mL] 162 ± 40 161 (45) 0.95
Mean LVESV at baseline [mL] 84 ± 30 81 (34) 0.82
Abbreviations as in Table 1
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on late PCI so far [9–11]. These concerns were 
addressed in the ancillary study to OAT trial — 
the OAT-NUC study dedicated to the analysis of 
infarct zone viability. It was based on SPECT and 
showed that 31% of patients did not have a pre-
served viability (severely reduced viability group) 
defined as at least 40% of the marker uptake [23]. 
The study demonstrated that the presence of in-
Figure 2A–F. Change in cardiac function and size for the two treatment strategies. Repeated measures analysis of 
variance for all patients (A–C) and for patients with left anterior descending artery (LAD) as the infarct-related artery 
(IRA) only (D–F). Percutaneous coronary intervention (PCI) + optimal medical therapy (OMT) group (dashed line), OMT 
alone group (solid line). Means and standard deviations (SD) are presented.
558 www.cardiologyjournal.org
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farct zone viability (moderately retained viability 
group) predicted an improvement in LVEF in the 
whole group, but no differences in the improvement 
in LV systolic function or volumes in relation to 
the treatment strategy (PCI + OMT vs. OMT) in 
patients with preserved viability were observed. 
However, the OAT-NUC study was limited by re-
producibility and accuracy of the SPECT used for 
the viability assessment. This method was shown 
to underestimate the size of necrosis in comparison 
to CMR due to its lower spatial resolution, and the-
refore the percentage of patients with moderately 
retained viability might have been overestimated 
[24]. It has been demonstrated that CMR should 
be currently considered as the gold standard of 
accuracy and reproducibility for assessing volumes, 
mass, and wall motion [25]. 
In spite of all of the considerations above, we 
decided to perform a single center randomized 
clinical trial assessing the results of late PCI with 
OMT vs. OMT alone, but only in patients with pre-
served infarct zone viability established by means 
of CMR. Because of the difficulties in recruiting 
patients to obtain the predefined sample size we 
proposed to the authors of other published studies 
on late PCI for the totally occluded IRA performed 
with the use of CMR, to develop a collaborative 
publication. None of these studies took into acco-
unt the role of preserved infarct zone viability in 
individual patients. With this approach, we were 
able to demonstrate that late PCI with OMT in the 
subgroup of patients with viable myocardium after 
MI is associated with improvement of both cardiac 
systolic function and size, over OMT alone. The 
opening of IRA seemed particularly efficacious in 
patients with LAD occlusion, which may suggest 
that the group of patients with the largest area of 
myocardium at risk may benefit most from reva-
scularization. 
Our findings are supported by the results 
of PCI in the group of stable patients with silent 
ischemia on stress imaging (a marker of a viable 
myocardium), which showed marked differences in 
LVEF, LVESV and LVEDV favoring late PCI [26]. 
It should be noted however that, contrary to the 
current analysis, total occlusion of an IRA was not 
required for randomization into treatment.
Limitations of the study
Our study is not free from limitations of an ex-
plorative, pooled data analysis. However, we have 
attempted to lower the existing inclusion bias by li-
miting the analysis to patients with LAD occlusion. 
It can be observed that the frequency of the use of 
some medications, which was considered optimal 
at the time when 2 of the analyzed studies were 
conducted, is no longer satisfactory [7, 20]. How-
ever, it is similar to the OAT trial, which is used as 
an evidence for current guidelines of management 
in acute MI [1]. Besides the use of ACE-I conside-
red as main drugs preventing LV remodeling was 
higher in the current analysis than in the OAT trial, 
which further supports the results. Furthermore, 
with this sample size we were unable to analyze 
clinical end-points. However, recently published 
results of the VIAMI-trial, which included stable 
patients with acute MI not treated with primary 
or rescue PCI and with viability by dobutamine 
echocardiography, demonstrated that PCI after at 
least 48 h improved outcomes in comparison to 
conservative strategy [27]. Our findings suggest 
that the improved event-free survival observed 
with late PCI of an IRA in the VIAMI-trial may 
be the consequence of an improved LV systolic 
performance and size.
Conclusions
In patients with preserved infarct zone via-
bility, OMT with late PCI for an occluded IRA 
(particularly LAD) is associated with improvement 
of LV systolic function and size over OMT alone. 
This study should be considered as introduction 
to a discussion on a routine use of late PCI of the 
occluded IRA in patients with preserved infarct 
zone viability.
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